Kamada Ltd. (KMDA) Posts Robust 2025 Financial Outlook with Revenue and EBITDA Growth Expectations
ByAinvest
Monday, Nov 10, 2025 5:40 pm ET1min read
KMDA--
Kamada Ltd (KMDA) reaffirms 2025 financial outlook with total revenues projected between $178 million and $182 million, and adjusted EBITDA between $40 million and $44 million, indicating significant revenue and EBITDA growth. The company operates in the healthcare sector, focusing on plasma-derived protein therapeutics, with a robust product portfolio and strong financial health. Favorable valuation ratios and positive analyst sentiment further support Kamada's growth trajectory.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet